{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:07:48Z","timestamp":1788826068832,"version":"build-2803163510"},"reference-count":124,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.humpath.2015.02.006","type":"journal-article","created":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T01:53:02Z","timestamp":1425088382000},"page":"789-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Prognostic factors in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"46","author":[{"given":"Ben","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2015.02.006_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2012.05.014","article-title":"Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update","volume":"44","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0010","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jclinpath-2012-201303","article-title":"Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers","volume":"66","author":"Henderson","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5858\/arpa.2010-0604-RA","article-title":"Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma","volume":"136","author":"Betta","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2015.02.006_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0031-1272874","article-title":"Update on malignant pleural mesothelioma","volume":"32","author":"Campbell","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.humpath.2015.02.006_bb0025","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/JTO.0000000000000181","article-title":"IASLC Staging Committee and Participating Institutions. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee","volume":"9","author":"Pass","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0030","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1159\/000321370","article-title":"A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma","volume":"80","author":"Tanrikulu","year":"2010","journal-title":"Respiration"},{"key":"10.1016\/j.humpath.2015.02.006_bb0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jjco\/hyq159","article-title":"Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan","volume":"41","author":"Nojiri","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","article-title":"Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis","volume":"256","author":"Ghanim","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.humpath.2015.02.006_bb0050","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1007\/s13277-014-1938-5","article-title":"Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma","volume":"35","author":"Yao","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0055","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/bjc.2013.815","article-title":"Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma","volume":"110","author":"Ghanim","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0060","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.ejca.2012.05.018","article-title":"Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma","volume":"48","author":"Blayney","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0065","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/01913120802454298","article-title":"New diagnostic and molecular characteristics of malignant mesothelioma","volume":"32","author":"Davidson","year":"2008","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0070","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossman","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","article-title":"Molecular changes in mesothelioma with an impact on prognosis and treatment","volume":"136","author":"Jean","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2015.02.006_bb0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma","volume":"54","author":"Edwards","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2010.01.002","article-title":"Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma","volume":"70","author":"Gaafar","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jso.21901","article-title":"Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations","volume":"104","author":"Rena","year":"2011","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0095","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ejcts.2009.08.027","article-title":"Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma","volume":"37","author":"Schramm","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.humpath.2015.02.006_bb0100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JTO.0b013e3182417da5","article-title":"Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group","volume":"7","author":"Levallet","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.2013.9","article-title":"The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma","volume":"108","author":"Pinato","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.anndiagpath.2014.02.005","article-title":"Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma","volume":"18","author":"Tsao","year":"2014","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0115","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1096-9896(1998110)186:3<300::AID-PATH180>3.0.CO;2-Q","article-title":"Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome","volume":"186","author":"Kumar-Singh","year":"1998","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0120","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2015.02.006_bb0125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0130","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0135","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0140","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0145","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0150","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/1471-2407-14-674","article-title":"A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice","volume":"14","author":"Linch","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0155","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.biochi.2009.11.004","article-title":"Neurotensin expression and outcome of malignant pleural mesothelioma","volume":"92","author":"Alifano","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.humpath.2015.02.006_bb0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10585-010-9365-5","article-title":"Tetraspanins and tumor progression","volume":"28","author":"Richardson","year":"2011","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.humpath.2015.02.006_bb0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3892\/or.2012.2116","article-title":"CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma","volume":"29","author":"Amatya","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.humpath.2015.02.006_bb0170","first-page":"1369","article-title":"Overexpression of CD26\/DPPIV in mesothelioma tissue and mesothelioma cell lines","volume":"26","author":"Amatya","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.humpath.2015.02.006_bb0175","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1158\/1078-0432.CCR-11-1990","article-title":"CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma","volume":"18","author":"Aoe","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0180","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1002\/cncr.26497","article-title":"Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma","volume":"118","author":"Kao","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0185","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/bjc.2014.117","article-title":"CD74: a new prognostic factor for patients with malignant pleural mesothelioma","volume":"110","author":"Otterstrom","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0190","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1309\/AJCP0F6WYBXGVDHX","article-title":"Tumor\/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis","volume":"141","author":"Righi","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0195","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2015.02.006_bb0200","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/modpathol.2011.144","article-title":"Epithelial-mesenchymal transition in malignant mesothelioma","volume":"25","author":"Fassina","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0463.2012.02931.x","article-title":"Expression of snail, twist, and Zeb1 in malignant mesothelioma","volume":"121","author":"Merikallio","year":"2013","journal-title":"APMIS"},{"key":"10.1016\/j.humpath.2015.02.006_bb0210","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.athoracsur.2013.01.012","article-title":"Snail expression is associated with a poor prognosis in malignant pleural mesotheliomas","volume":"95","author":"Kobayashi","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.humpath.2015.02.006_bb0215","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejcts.2010.05.007","article-title":"Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma","volume":"39","author":"Watzka","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.humpath.2015.02.006_bb0220","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: A study of VEGF, FGF-1 and \u22122, and TGF\u03b2 expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0230","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0235","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2011.06.007","article-title":"The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin\/gemcitabine","volume":"75","author":"Kao","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0240","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1183\/09031936.00154009","article-title":"A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma","volume":"36","author":"Tabata","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.humpath.2015.02.006_bb0245","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1245\/s10434-012-2506-0","article-title":"Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM)","volume":"19","author":"Yoneda","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0250","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000087376","article-title":"Serum PDGF-AB in pleural mesothelioma","volume":"26","author":"Filiberti","year":"2005","journal-title":"Tumour Biol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0255","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2570::AID-CNCR12>3.0.CO;2-F","article-title":"Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma","volume":"85","author":"Ohta","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0260","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2015.02.006_bb0265","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/02841860500468927","article-title":"Expression of bcl-2 family members in malignant pleural mesothelioma","volume":"45","author":"O\u2019Kane","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0270","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejcts.2010.02.012","article-title":"May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?","volume":"38","author":"Mineo","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.humpath.2015.02.006_bb0275","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.yexmp.2012.04.001","article-title":"Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients","volume":"93","author":"Bahnassy","year":"2012","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0280","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/1097-0142(20010901)92:5<1245::AID-CNCR1444>3.0.CO;2-G","article-title":"p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma","volume":"92","author":"Bongiovanni","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0285","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2217\/fon.13.261","article-title":"Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma","volume":"10","author":"Mairinger","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0290","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jcp.2010.076794","article-title":"FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma","volume":"63","author":"Chung","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0295","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.semcancer.2004.04.002","article-title":"The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer","volume":"14","author":"Nachmias","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0300","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/path.2121","article-title":"Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma","volume":"211","author":"Gordon","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0305","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.humpath.2006.12.013","article-title":"Expression of inhibitors of apoptosis (IAP) family members in malignant mesothelioma","volume":"38","author":"Kleinberg","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0310","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00428-013-1373-9","article-title":"Is survivin expression prognostic or predictive in malignant pleural mesothelioma?","volume":"462","author":"Hmeljak","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2015.02.006_bb0315","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0320","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0325","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1158\/0008-5472.CAN-05-0127","article-title":"SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure","volume":"65","author":"Cacciotti","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0330","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","article-title":"PTEN expression is a strong predictor of survival in mesothelioma patients","volume":"33","author":"Opitz","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.humpath.2015.02.006_bb0335","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s13277-012-0615-9","article-title":"PTEN protein expression in malignant pleural mesothelioma","volume":"34","author":"Agarwal","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0340","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JTO.0000000000000055","article-title":"PI3K\/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy","volume":"9","author":"Bitanihirwe","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0345","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<740::AID-IJC12>3.0.CO;2-5","article-title":"Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes","volume":"78","author":"Mutti","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0350","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/1097-4652(200010)185:1<126::AID-JCP12>3.0.CO;2-2","article-title":"Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro","volume":"185","author":"Porta","year":"2000","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0355","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/jcp.22600","article-title":"Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications","volume":"226","author":"Calabr\u00f2","year":"2011","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0360","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0365","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0370","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","article-title":"Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0375","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0380","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0300060513504163","article-title":"The value of inflammatory parameters in the prognosis of malignant mesothelioma","volume":"42","author":"Abakay","year":"2014","journal-title":"J Int Med Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0385","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/bjc.2013.504","article-title":"Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma","volume":"109","author":"Meniawy","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0390","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0395","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.humpath.2015.02.006_bb0400","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/JTO.0b013e3181989ddb","article-title":"Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor","volume":"4","author":"Al\u00ec","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0405","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0410","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Righi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0415","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0420","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-012-1965-0","article-title":"A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma","volume":"70","author":"Zimling","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0425","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdr324","article-title":"The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma","volume":"23","author":"Er\u010dulj","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0430","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/JTO.0b013e3182653d31","article-title":"DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy","volume":"7","author":"Er\u010dulj","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0435","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cllc.2013.04.013","article-title":"ERCC1, MLH1, MSH2, MSH6, and \u03b2III-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma","volume":"14","author":"Ting","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0440","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/JTO.0b013e318260deaa","article-title":"Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma","volume":"7","author":"Christoph","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0445","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/JTO.0b013e318283da3e","article-title":"Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma","volume":"8","author":"Lustgarten","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0450","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1699-0463.1998.tb01376.x","article-title":"Immunoreactivity of pleural malignant mesotheliomas to glutathione S-transferases","volume":"106","author":"Dejmek","year":"1998","journal-title":"APMIS"},{"key":"10.1016\/j.humpath.2015.02.006_bb0455","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/BF01221194","article-title":"Glutathione S-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study","volume":"122","author":"Segers","year":"1996","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0460","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0169-5002(95)00549-8","article-title":"Evaluation and prognostic value of DNA content and of morphometric parameters in malignant mesothelioma using digital image analysis","volume":"14","author":"Segers","year":"1996","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0465","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10555-007-9104-9","article-title":"Osteopontin: regulation in tumor metastasis","volume":"27","author":"Wai","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.humpath.2015.02.006_bb0470","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cytogfr.2008.08.001","article-title":"Osteopontin: role in immune regulation and stress responses","volume":"19","author":"Wang","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.humpath.2015.02.006_bb0475","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2015.02.006_bb0480","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1309\/TWCQV536WWRNEU51","article-title":"Prognostic role of osteopontin expression in malignant pleural mesothelioma","volume":"130","author":"Cappia","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0485","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0169-5002(99)00044-6","article-title":"Prognostic value of the serum tumour markers Cyfra 21\u20131 and tissue polypeptide antigen in malignant mesothelioma","volume":"25","author":"Schouwink","year":"1999","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0490","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.ejca.2005.04.019","article-title":"Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma","volume":"41","author":"O'Kane","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0495","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1158\/0008-5472.CAN-08-4523","article-title":"Estrogen receptor-beta affects the prognosis of human malignant mesothelioma","volume":"69","author":"Pinton","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0500","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/JTO.0b013e31822f6544","article-title":"Sustained expression of steroid receptor coactivator SRC-2\/TIF-2 is associated with better prognosis in malignant pleural mesothelioma","volume":"7","author":"Jennings","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0505","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jcp.2008.060533","article-title":"Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma","volume":"62","author":"Lindholm","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0510","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U","article-title":"Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma","volume":"92","author":"Thyl\u00e9n","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0515","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","article-title":"Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma","volume":"82","author":"Creaney","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0520","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.humpath.2015.02.006_bb0525","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2217\/14622416.9.8.1069","article-title":"The serine protease HtrA1 is a novel prognostic factor for human mesothelioma","volume":"9","author":"Baldi","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.humpath.2015.02.006_bb0530","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/bjc.2013.66","article-title":"The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma","volume":"108","author":"Dalton","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0535","doi-asserted-by":"crossref","first-page":"e7016","DOI":"10.1371\/journal.pone.0007016","article-title":"Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target","volume":"4","author":"Crispi","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2015.02.006_bb0540","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2007.08.035","article-title":"Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up","volume":"59","author":"Destro","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0545","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12094-013-1146-6","article-title":"Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma","volume":"16","author":"Cedr\u00e9s","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.humpath.2015.02.006_bb0550","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","article-title":"Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma","volume":"13","author":"Tabata","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0555","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.lungcan.2014.06.018","article-title":"The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma","volume":"85","author":"Giroux Leprieur","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0560","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Arzt","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0565","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/jnci\/95.8.598","article-title":"Using gene expression ratios to predict outcome among patients with mesothelioma","volume":"95","author":"Gordon","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2015.02.006_bb0570","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-04-2181","article-title":"Validation of genomics-based prognostic tests in malignant pleural mesothelioma","volume":"11","author":"Gordon","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0575","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jnci\/djp061","article-title":"Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma","volume":"101","author":"Gordon","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2015.02.006_bb0580","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"L\u00f3pez-R\u00edos","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0585","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1078-0432.CCR-0607-3","article-title":"Gene expression profiles predict survival and progression of pleural mesothelioma","volume":"10","author":"Pass","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0590","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reyni\u00e8s","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0595","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/0008-5472.CAN-09-3993","article-title":"hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma","volume":"70","author":"Pass","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0600","doi-asserted-by":"crossref","first-page":"e10612","DOI":"10.1371\/journal.pone.0010612","article-title":"Second generation sequencing of the mesothelioma tumor genome","volume":"5","author":"Bueno","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2015.02.006_bb0605","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2014.08.004","article-title":"Identification of actionable mutations in malignant pleural mesothelioma","volume":"86","author":"Shukuya","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2015.02.006_bb0610","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2015.02.006_bb0615","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ijc.29015","article-title":"Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI\/SNF genes","volume":"136","author":"Yoshikawa","year":"2015","journal-title":"Int J Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.humpath.2015.02.006_bb0620","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.lungcan.2005.03.012","article-title":"Molecular prognostic markers in malignant mesothelioma","volume":"49","author":"Kumar","year":"2005","journal-title":"Lung Cancer"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817715000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817715000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T14:08:59Z","timestamp":1717769339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817715000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0046817715000714"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2015.02.006","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2015.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}